Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches (CAPSASENS)

15 giugno 2026 aggiornato da: Nantes University Hospital
The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Category 2 Study (Interventional Research with Minimal Risks and Constraints), monocentric, uncontrolled, non-randomized, open-label and prospective.

This study involves conducting tests and questionnaires before and 1 month after the application of a patch administered as part of standard clinical practice.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Francia
      • Nantes, Francia
        • Nantes university hospital
        • Contatto:
          • Nantes University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Men or women ≥ 18 years old.
  • Patients suffering from chronic pelvi-perineal neuralgia (>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).
  • Patients who have signed the informed consent form for the study at the inclusion visit.
  • Women must meet one of the following criteria at the time of inclusion:
  • Use adequate contraceptive measures;
  • or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);
  • or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;
  • or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.

Exclusion Criteria:

  • Patients under guardianship, curatorship, or legal protection.
  • Pregnant or breastfeeding women.
  • Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components.
  • Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).
  • Patients not affiliated with the French Social Security system.
  • Patients with insufficient cooperation and/or understanding to strictly comply with the protocol requirements.
  • Patients who have taken analgesics within the 12 hours prior to measurements.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Pain sensitization parameter testing

Pre-inclusion visit (routine care consultation): Verification of inclusion and exclusion criteria.

Inclusion visit (Day 0): Consent signing, questionnaires (ConvergencePP Score/Central Sensitization Inventory, DN4), and a series of tests, followed by the application of the high-concentration capsaicin patch (PCHC) (performed during routine care).

Day 30 visit (±7 days): Questionnaires (same as V1 + PGI-c) and a series of tests.
Altro: Quantitative Sensory Testing and questionnaires
Quantitative Sensory Testing and questionnaires

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite criterion
Lasso di tempo: Difference between Day 0 and Day 30
Composite criterion constructed from a Principal Component Analysis including the differences between Day 0 (before patch application) and Day 30 in pain perception thresholds (to cold, heat, pressure, and mechanical stimulation) in both the area treated with the high-concentration capsaicin patch and the corresponding dermatome, as well as the change in the pain receptive field area in the treated zone and the area under the curve of temporal summation measurements.
Difference between Day 0 and Day 30

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (1)
Lasso di tempo: Between before and 30 days after patch application
Difference in pressure pain thresholds in the treated area
Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (2)
Lasso di tempo: Between before and 30 days after patch application
Difference in mechanical stimulation pain thresholds
Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (3)
Lasso di tempo: Between before and 30 days after patch application
Difference in cold pain thresholds in the treated area
Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (4)
Lasso di tempo: Between before and 30 days after patch application
Difference in heat pain thresholds in the treated area
Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (5)
Lasso di tempo: Between before and 30 days after patch application
Difference in pain receptive field area
Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (1)
Lasso di tempo: Between before and 1 month after patch application.

Difference in pressure pain thresholds in an area of the dermatome not directly treated by the patch:

  • Ipsilateral retro-malleolar groove (S2 root) for inferior cluneal nerve neuralgia treatment,
  • Posterior iliac crest relief, 7 cm from the midline (L1) for ilio-inguinal or ilio-hypogastric neuralgia treatment,
  • Perineal body (S4) for sacrococcygeal plexus neuralgia treatment.
Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (2)
Lasso di tempo: Between before and 1 month after patch application.
Difference in mechanical stimulation pain thresholds in an area of the dermatome not directly treated by the patch
Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (3)
Lasso di tempo: Between before and 1 month after patch application.
Difference in cold pain thresholds in an area of the dermatome not directly treated by the patch.
Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (4)
Lasso di tempo: Between before and 1 month after patch application.
Difference in heat pain thresholds in an area of the dermatome not directly treated by the patch.
Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (5)
Lasso di tempo: Between before and 1 month after patch application.
Difference in the area under the curve of temporal summation measurements in the treated area
Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (6)
Lasso di tempo: Between before and 1 month after patch application.
Difference in the duration of pain persistence after the end of temporal summation (in seconds).
Between before and 1 month after patch application.
Measure the patient's therapeutic response to the treatment
Lasso di tempo: Day 30
Patient Global Impression of Change (PGI-C). The therapeutic response is defined as a patient who scores 1 to 3 on the PGI-C.
Day 30
Evaluate the predictive value of temporal summation with regard to the therapeutic response to the high-concentration capsaicin patch
Lasso di tempo: Between before and 1 month after patch application.
Investigation of a relevant threshold for temporal summation to predict the therapeutic response. Quantification of the positive predictive value.
Between before and 1 month after patch application.
Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data
Lasso di tempo: Between before and 1 month after patch application

Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data. The Convergences PP score is a clinical questionnaire used to diagnose sensitization in the pelvic region. A score is considered positive from 5/10 (sensitivity = 95%, specificity = 87%).

The Central Sensitization Inventory (CSI) is a self-administered questionnaire used to diagnose central sensitization. A score is considered positive from 40/100.

Correlations between the Convergences PP score, CSI, and semi-objective sensitization data (pain thresholds and temporal summation) will be measured using Spearman's correlation coefficient to explore the relationships between these variables.
Between before and 1 month after patch application

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Nantes University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 settembre 2026

Completamento primario (Stimato)

1 marzo 2028

Completamento dello studio (Stimato)

1 marzo 2028

Date di iscrizione allo studio

Primo inviato

15 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 giugno 2026

Primo Inserito (Effettivo)

22 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • RC25_0536

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi